MetaCap

Bambusa Therapeutics SEC Filings

NASDAQ: BBTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

16.00+0.45 (+2.89%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Bambusa Therapeutics filing overview

This page lists 11 recent SEC filings by Bambusa Therapeutics (BBTX), including 5 4, 1 SCHEDULE 13D, 1 SCHEDULE 13G, 1 8-K. The latest current report (8-K), used to disclose material events such as earnings releases and executive changes, was filed on Nov 3, 2026. Form 10-K is the audited annual report, 10-Q the quarterly report, 8-K covers material events, and Form 4 reports insider transactions. All documents link directly to SEC EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

BBTX SEC filings

Bambusa Therapeutics SEC filings
FiledFormDescriptionDocument
Nov 6, 2026SCHEDULE 13DBeneficial ownership report (activist)View on EDGAR
Nov 5, 2026SCHEDULE 13GBeneficial ownership report (passive)View on EDGAR
Nov 3, 20264Statement of changes in beneficial ownershipView on EDGAR
Nov 3, 20268-KAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Regulation FD DisclosureView on EDGAR
Nov 2, 20264Statement of changes in beneficial ownershipView on EDGAR
Nov 2, 20264Statement of changes in beneficial ownershipView on EDGAR
Nov 2, 20264Statement of changes in beneficial ownershipView on EDGAR
Nov 2, 20264Statement of changes in beneficial ownershipView on EDGAR
Oct 30, 2026424B4ProspectusView on EDGAR
Oct 26, 2026S-1/ARegistration statement (amendment)View on EDGAR
Oct 9, 2026S-1Registration statementView on EDGAR

Related